Italian authorities on January 21 warned that the delay in the distribution of the vaccine for acute respiratory infections COVID-19 will continue to affect Italy’s vaccination campaign in the short term.
|Some European countries plan to take legal action with US pharmaceutical company Pfizer if the vaccine is not given enough.|
“We have been informed by Pfizer that we will receive 20% less vaccine next week,” said COVID-19 Special Commissioner of Emergency, Mr. Domenico Arcuri.
Mr. Arcuri said the country had a 29% cut in its vaccine supply from Pfizer last week, emphasizing that the delay in this transfer has a clear impact on vaccination plans at some point in time. Beginners need the second required shot (21 days after the first shot).
According to Mr. Arcuri, at the time before January 16, the country deployed injections for an average of 80,000 people / day, but after this date, this number has decreased to about 28,000 people.
Mr. Domenico Arcuri said the Italian government is considering pursuing legal action against Pfizer because of its unilateral move. Meanwhile, Pfizer earlier this month pledged that deliveries to the EU will return to normal starting from January 25-30.
Vaccination was deployed to 82.3% of the 1,558,635 doses of vaccine that Italy has received, most of which are vaccines supplied by Pfizer. However, the company recently announced that the progress of vaccine delivery to the European Union (EU) member countries will slow down due to a number of objective reasons.
A similar move was made after Italy to Poland.
The Polish government has warned that it will take legal action against Pfizer if the pharmaceutical group fails to overcome the impact of reducing Polish vaccine supplies.
Polish government spokesman Piotr Muller said on January 22 that the legal sanctions plan is being considered by the government and could be introduced next month if the vaccine is not provided as stated. producer father.
The warning was issued by Poland after it received only 176,000 doses of Pfizer’s Covid-19 vaccine this week, less than half of what was expected. According to the Polish government, the lack of a planned supply of vaccines will affect the progress of the vaccination program.
The German side also expressed frustration with the announcement of the US pharmaceutical company. The German Ministry of Health calls Pfizer’s announcement surprising and regrettable, noting that it has committed a delivery date until mid-February.
Six other EU countries, Sweden, Denmark, Finland, Lithuania, Latvia and Estonia, have called the situation “unacceptable” and warned it “reduces the reliability of the vaccination process”. They urged the EU to put pressure on Pfizer-BioNTech.
EU Commission President Ursula von der Leyen was then reassured, she said, having been assured by Pfizer’s chief executive that all orders were delivered in the first quarter of the year.
Canada is also affected by its supply of vaccines coming from a Pfizer factory in Belgium.
Norway, not a member of the EU, said on January 22 that Pfizer is temporarily reducing the number of doses of vaccine delivered to the country from next week.
Earlier, there was information from a French daily newspaper that the European Pharmaceutical Agency (EMA) found that the Pfizer vaccine for mass vaccination was of inferior quality to the one used in clinical trials.
The Pfizer / BioNTech vaccine is based on a technology called “information RNA” (ARNm). But the EMA found that the experimental vaccine vials contained 69-81 percent RNA, while the commercial vials contained only 59 percent.
At first the explanation was “due to changing production methods to increase output to keep up with market demand”. Only then did Pfizer announced that it had found a way to ensure that the rate of RNA reached 75% relative to the level of the clinical trial.
EMA has not commented on this information yet.
|Pfizer / BioNTech vaccine vials must be stored at -70 ° C. Photo: Reuters|
In addition to Pfizer-BioNTech, the European Commission reached an agreement with five other pharmaceutical companies to buy hundreds of millions of vaccines, after they passed clinical trials: AstraZeneca: 400 million doses of Sanofi-GSK: 300 million Johnson & Johnson dose: 400 million doses of CureVac: 405 million doses of Moderna: 160 million doses
The committee concluded initial negotiations with another company, Novavax, in quantities of up to 200 million doses.
It is expected that the EU will also consider approving the Russian Sputnik V vaccine until the end of this January.